drugset / Trial / NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

NCT02409680 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

Available data suggest that low dose aspirin may be a safe, widely available and inexpensive intervention that may significantly reduce the risk of preterm birth. However, this possibility needs to be proven in a properly designed randomized controlled trial (RCT) with preterm birth as the primary outcome. Such a clinical trial in a racially, ethnically and geographically diverse population could best be accomplished by the established infrastructure of the Global Network for Women's and Children's Health Research (GN).

Timeline

Start
2016-03-23
Primary completion
2019-04-11
Completion
2019-04-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 81 mg —

Indications

No indication recorded.